Oncurious NV Appoints Prof Dr Peter Carmeliet as its Chief Scientific Strategy Advisor
(Thomson Reuters ONE) -
Leuven, June 26, 2015 - Oncurious NV, an oncology company focused on the
development of innovative medicines for the treatment of pediatric tumors, today
announces the appointment of Prof Dr Peter Carmeliet as its Chief Scientific
Strategy Advisor. Oncurious is a new oncology company and a joint venture
between ThromboGenics NV and VIB, a leading life sciences institute in Flanders
(Belgium).
Since 15 years Prof Carmeliet (VIB Vesalius Research Center, KU Leuven) has
focused his research interests on unravelling the molecular basis ofhas focused
since 15 years its research interests on unraveling the molecular basis of
neuro-vascular biological processes and diseases, and translating these genetic
insights in therapeutic concepts - with the ultimate aspiration to develop novel
treatmentsThe Vesalius Research Center (VRC) has focused since 15 years its
research interests on unraveling the molecular basis of neuro-vascular
biological processes and diseases, and translating these genetic insights in
therapeutic concepts - with the ultimate aspiration to develop novel treatments
neuro-vascular biological processes and diseases, and translating these genetic
insights into therapeutic concepts - with the ultimate aspiration to develop
novel treatments.
Research conducted by Prof Carmeliet's team at VIB/KU Leuven, in collaboration
with Prof Rakesh Jain from the Massachusetts General Hospital at Harvard
(Boston), generated the first pre-clinical data on the use of human monoclonal
antibodies against placental growth factor (PlGF) in the treatment of
medulloblastoma. Based on the positive results, TB-403 will be now further
developed by Oncurious for the treatment of pediatric tumors.
Prof Dr Peter Carmeliet comments: "I am pleased with this opportunity to support
the translation of pre-clinical research conducted at VIB/KU Leuven and other
world leading institutes into potential novel cancer treatments. Working with
Oncurious NV gives me the occasion to remain very closely involved in the
process of developing a drug for clinical use."
Dr Patrik De Haes, CEO of ThromboGenics NV and Executive Chairman of Oncurious
NV: We are delighted that Prof Carmeliet has accepted the role of Chief
Scientific Strategy Advisor with Oncurious. Professor Carmeliet is a globally
renowned leader in the field of oncology research and its underlying biological
processes. His scientific insights, research and in-depth expertise will be
very valuable as the Oncurious team progresses its current clinical development
of TB-403 for the treatment of pediatric brain tumors, I am confident that his
insights will, in time, allow Oncurious to build an oncology pipeline and become
an international leader in developing novel cancer therapies."
For further information please contact:
+------------------------------------+-------------------------------+
| Oncurious NV / ThromboGenics NV: | Citigate Dewe Rogerson |
| Wouter Piepers | David Dible/Malcolm Robertson |
| +32 16 75 13 10 / +32 478 33 56 32 | Tel: +44 20 7638 9571 |
| wouter.piepers(at)thrombogenics.com | david.dible(at)citigatedr.co.uk |
| | |
| VIB/ KU Leuven : | |
| Peter Carmeliet | |
| Peter.carmeliet(at)vib-kuleuven.be | |
| | |
+------------------------------------+-------------------------------+
About Oncurious NV
Oncurious NV is an oncology company focused on the development of innovative
medicines for the treatment of pediatric brain tumors. Oncurious is a joint
venture between ThromboGenics and VIB, a leading life science research institute
in Flanders (Belgium).
Oncurious plans to initiate a Phase I/IIa clinical program with TB-403 for the
treatment of medulloblastoma, a rare, life-threatening brain tumor that mainly
affects children. Enrolment of the first patient is expected by the end of 2015.
BioInvent International is Oncurious' co-development partner for the planned
Phase I/IIa TB-403 clinical trial.
More information on Oncurious can be found at www.oncurious.com
Important information about forward-looking statements
Certain statements in this press release may be considered "forward-looking".
Such forward-looking statements are based on current expectations, and,
accordingly, entail and are influenced by various risks and uncertainties. The
Company therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume an obligation to update or
revise any forward-looking statement, whether as a result of new information,
future events or any other reason. Additional information concerning risks and
uncertainties affecting the business and other factors that could cause actual
results to differ materially from any forward-looking statement is contained in
the Company's Annual Report.
This press release does not constitute an offer or invitation for the sale or
purchase of securities or assets of ThromboGenics in any jurisdiction. No
securities of ThromboGenics may be offered or sold within the United States
without registration under the U.S. Securities Act of 1933, as amended, or in
compliance with an exemption therefrom, and in accordance with any applicable
U.S. state securities laws.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: ThromboGenics NV via GlobeNewswire
[HUG#1931734]
Unternehmensinformation / Kurzprofil:
Datum: 26.06.2015 - 08:00 Uhr
Sprache: Deutsch
News-ID 403242
Anzahl Zeichen: 6647
contact information:
Town:
Leuven
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 159 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Oncurious NV Appoints Prof Dr Peter Carmeliet as its Chief Scientific Strategy Advisor"
steht unter der journalistisch-redaktionellen Verantwortung von
ThromboGenics NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
